Automakers Are Expanding EV Charging Options, Prioritizing Convenience and Accessibility for Drivers
By GlobeNewswire Published on June 27, 2025, 20:03 IST
IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) — With more than 5.2 million EVs now on U.S. roads, the need for convenient and reliable charging continues to grow. Automakers are responding with new partnerships and upgrades that make charging easier, especially for long-distance drivers.
A Media Snippet accompanying this announcement is available in this link.
Kia Corporation is helping meet that demand by giving its EV owners access to more than 21,500 additional Supercharging stations nationwide. These join the 22,000-plus public fast-charging stations already available, significantly expanding the charging network. Drivers can locate and charge at these stations using the Kia Access app, which also provides real-time updates on station availability and pricing.
For owners of the Kia EV6, EV9 and Niro with CCS1 ports, the update allows charging at Tesla Superchargers using a compatible adapter. This feature is built directly into the app for a seamless user experience.
These additions are part of a larger industry effort to reduce 'charge anxiety' and make long-distance travel accessible by expanding options and making them easier to find and use. As more automakers adopt shared charging infrastructure, drivers benefit from greater flexibility and more reliable access.
'Access and ease are top priorities for EV drivers,' said James Bell, head of corporate communications at Kia America. 'Expanding our network and making it user-friendly helps support the future of mobility and brings real peace of mind to our customers.'
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
10 minutes ago
- Business Upturn
PS Miner Announces Enhanced Payment Options for Cloud Mining Participants
By GlobeNewswire Published on June 28, 2025, 01:09 IST Eastleigh, England, UK, June 27, 2025 (GLOBE NEWSWIRE) — Hampshire, United Kingdom – June 27, 2025 – PS Miner, a cloud mining platform, has announced the integration of cryptocurrency wallet payments for its services, aiming to streamline the process for users interested in cloud mining. The platform also offers opportunities for participants to potentially earn passive income through its various mining packages. The digital asset market continues to evolve in 2025, and cloud mining remains a popular avenue for individuals seeking to engage with cryptocurrency mining without the need for personal equipment. PS Miner states that it allows users to rent computing power and receive daily payouts based on their share of this power. The platform highlights its use of AI-based mining strategies, which it claims are designed to optimize investor returns. How to Engage with PS Miner Individuals interested in using the PS Miner platform can follow these steps: Users can visit the official PS Miner website ( ) and create an account using their email address. ) and create an account using their email address. The platform offers various cloud mining packages, allowing users to select an option based on their needs. Examples of available packages include: New User Experience Contract: Investment: $100, Contract Period: 2 days, Daily Income: $3.6, Expiration Income: $100 + $7.2 Investment: $500, Contract Period: 5 days, Daily Income: $6.35, Expiration Income: $500 + $31.75 Investment: $3,000, Contract Period: 20 days, Daily Income: $42, Expiration Income: $3,000 + $840 Investment: $10,000, Contract Period: 45 days, Daily Income: $160, Expiration Income: $10,000 + $7,200 Investment: $50,000, Contract Period: 50 days, Daily Income: $900, Income at Maturity: $50,000 + $45,000 The platform supports multiple cryptocurrencies for payment, including stablecoins such as USDT-TRC 20, BTC, XRP, ETH, LTC, USDC, BNB, USDT-ERC 20, BCH, Doge, and SOL. Upon successful recharge and package selection, the system is designed to automatically commence mining. Users can monitor their mining income in real time on the platform. Mining income is reportedly paid daily to the user's account. Withdrawals are available once the account balance reaches $100, with funds transferable to a user's crypto wallet or used for further contract purchases. PS Miner Platform Features PS Miner highlights several aspects of its operations: The company states it utilizes renewable energy sources such as wind, water, and solar to power its mining operations. PS Miner reports using ASIC miners and GPU equipment, emphasizing its experience in cloud mining operations. The majority of PS Miner's funds are reportedly stored in offline cold wallets, and the platform claims to employ security measures like McAfee® SECURE protection and Cloudflare® SECURE protection. The PS Miner team is described as being composed of blockchain industry professionals and IT engineers. The platform emphasizes that XRP mining on their service does not require users to own hardware, as the platform manages the computing power. PS Miner offers 24/7 online customer service to address user inquiries. The platform's integration of crypto wallet payments aims to simplify the payment process for users by bypassing certain registration and private key management steps. About PS Miner PS Miner describes itself as a global cryptocurrency mining company, stating it provides cloud mining services to over 7 million users across more than 180 countries and regions. The company reports utilizing advanced artificial intelligence technology and clean energy sources in its operations, aiming to make cryptocurrency mining more sustainable and accessible. Contact Information: Email: [email protected] Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
10 minutes ago
- Business Upturn
Urbanica Launches Premium Ergonomic Office Furniture Tailored for Home and Hybrid Workspaces
LOS ANGELES, June 27, 2025 (GLOBE NEWSWIRE) — Urbanica Furniture, a family-owned brand with over three decades of experience in high-quality furniture manufacturing, has unveiled its newest collection of ergonomic office solutions, built for today's modern professionals. This new launch includes height-adjustable desks, ergonomic chairs, and workspace accessories—all designed with comfort, sustainability, and flexibility in mind. Urbanica's ergonomic desk is designed to enhance comfort and style in modern workspaces 'At Urbanica, we believe great furniture should empower people to do their best work—no matter where they are,' said Urbanica. 'From remote professionals and startup teams to creative studios, our mission is to make it easy and affordable to create a workspace that supports wellness, focus, and productivity.' Tailored Solutions for Every Industry and Team Urbanica's ergonomic products are crafted to meet the unique demands of various work environments: Tech Startups & Agencies : Adaptable furniture boosts team agility and reflects a modern aesthetic. : Adaptable furniture boosts team agility and reflects a modern aesthetic. Creative Studios : Stylish, functional pieces support long hours of focused design work. : Stylish, functional pieces support long hours of focused design work. Consulting & Finance: Sleek, professional setups help maintain client-ready presentation and long-term comfort. Flexible, Stylish, and Sustainable The product line includes the Novo, Muse, Onyx, and Seashell chairs; height-adjustable desks; mini standing desks; and modular workstations. Customers can build their own furniture bundles, creating office layouts that reflect their workflows. Urbanica simplifies the entire process—from design to delivery—by managing logistics and white-glove installation in-house. The direct-to-consumer model eliminates markup, offering up to 50% savings compared to traditional office furniture vendors. Commitment to Wellness and the Planet Urbanica integrates environmental responsibility into every step. For each purchase, the company plants a tree through global reforestation efforts, including mangrove restoration in Africa. Eco-conscious materials, minimal packaging, and long-lasting product design reduce waste and carbon footprint. Explore More To browse the full collection or create a personalized office bundle, visit . Media Contact: Urbanica FurnitureURBANICA [email protected]
Business Upturn
10 minutes ago
- Business Upturn
Pliant Therapeutics Provides Update on BEACON-IPF
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events. Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial. At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p>0.05) and 8 mL (p>0.05), respectively, compared to placebo. The full results from BEACON-IPF will be submitted for future publication. 'Although the decision to discontinue bexotegrast in IPF is disappointing for us and the many patients in need of new treatment options, we believe it is the right decision to protect patient safety,' said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. 'We sincerely thank all patients, their caregivers, the study investigators and their research teams who were part of the BEACON-IPF clinical program for their extensive efforts.' Oncology Phase 1 Enrollment Continues PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, designed to block TGF-β activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts. Early Programs Supported by Proprietary Platform The Company's drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α 7 β 1 targeting muscular dystrophies. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'intend,' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding development plans for PLN-101095, PLN-101325 and the Company's proprietary platform; and the Company's efforts to align its workforce and operations for its next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 which are available on the SEC's website at Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc. [email protected]
